Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials-Reference-Cited by-同舟云学术

Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

Published:2019-09-11 Issue:509 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Lin Ann¹²^ORCID,Giuliano Christopher J.¹²^ORCID,Palladino Ann¹,John Kristen M.¹³^ORCID,Abramowicz Connor¹⁴,Yuan Monet Lou¹⁵,Sausville Erin L.¹,Lukow Devon A.¹²,Liu Luwei¹²,Chait Alexander R.¹^ORCID,Galluzzo Zachary C.¹^ORCID,Tucker Clara¹²^ORCID,Sheltzer Jason M.¹^ORCID

Affiliation:

1. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA.

2. Stony Brook University, Stony Brook, NY 11794, USA.

3. Hofstra University, Hempstead, NY 11549, USA.

4. New York Institute of Technology, Glen Head, NY 11545, USA.

5. Syosset High School, Syosset, NY 11791, USA.

Abstract

CRISPR reveals that many cancer drug targets are dispensable for cell proliferation and identifies CDK11 as the target of one mischaracterized agent.

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)